Latest News
April 3, 2025
Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics
Team Brings Deep Experience in Oncology Drug Development, Clinical Operations and Building Biotechnology Companies
February 26, 2025
Crescent Biopharma to Present at the TD Cowen 45th Annual Health Care Conference
Company to highlight lead program CR-001, a tetravalent VEGF1 x PD-1 bispecific antibody in development for treating solid tumors
February 24, 2025
Crescent Biopharma Strengthens Leadership Team with Appointment of Three Key Executives
New appointees reinforce the Company’s momentum in building a leading oncology therapeutics company
November 12, 2024
Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024
Company to highlight lead program CR-001, a tetravalent VEGF1 x PD-1 bispecific antibody in development for treating solid tumors
November 11, 2024
Crescent Biopharma Appoints Susan Moran, MD, MSCE, and Alexandra Balcom, MBA, CPA, to Board of Directors
New appointees, along with recently appointed Directors Peter Harwin and Interim CEO Jonathan Violin, PhD, provide a strong foundation for the company
October 29, 2024
GlycoMimetics enters into acquisition agreement with Crescent Biopharma
Following Closing, the combined company will advance Crescent’s portfolio of precision-engineered biologics to improve outcomes for patients with solid tumors